SOURCE: WayPoint Biomedical, Inc.

December 15, 2005 06:30 ET

WayPoint Biomedical Receives First International Order for 60,000 Pregnancy Kits From International Relief Group in Nigeria

HUNTINGTON BEACH, CA -- (MARKET WIRE) -- December 15, 2005 -- WayPoint Biomedical, Inc. (OTC: WYPH) has closed their first order for 60,000 Pregnancy (hCG) Test Kits with an International Relief Group that provides medical aid to Nigeria.

According to WayPoint Director of Sales and Marketing, Phill Richer, "We are very excited about breaking into the international medical arena with our rapid test range and we see this as the first of many future international opportunities." Mr. Richer also adds, "Although manufacturing has slowed down due to the holiday season, we expect the test strips to be completed and shipped by early January."

About WayPoint Biomedical, Inc.:

WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (OTC: WYPH), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit,

Included in this release are certain "forward-looking'' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Contact Information